Literature DB >> 25678838

Analysis of efficacy differences between caudal and lumbar interlaminar epidural injections in chronic lumbar axial discogenic pain: local anesthetic alone vs. local combined with steroids.

Laxmaiah Manchikanti1, Vidyasagar Pampati1, Ramsin M Benyamin2, Mark V Boswell3.   

Abstract

STUDY
DESIGN: Comparative assessment of randomized controlled trials of caudal and lumbar interlaminar epidural injections in chronic lumbar discogenic pain.
OBJECTIVE: To assess the comparative efficacy of caudal and lumbar interlaminar approaches of epidural injections in managing axial or discogenic low back pain. SUMMARY OF BACKGROUND DATA: Epidural injections are commonly performed utilizing either a caudal or lumbar interlaminar approach to treat chronic lumbar axial or discogenic pain, which is pain exclusive of that associated with a herniated intervertebral disc, or that is due to degeneration of the zygapophyseal joints, or due to dysfunction of the sacroiliac joints, respectively. The literature on the efficacy of epidural injections in managing chronic axial lumbar pain of presumed discogenic origin is limited.
METHODS: The present analysis is based on 2 randomized controlled trials of chronic axial low back pain not caused by disc herniation, radiculitis, or facet joint pain, utilizing either a caudal or lumbar interlaminar approach, with a total of 240 patients studied, and a 24-month follow-up. Patients were assigned to receive either local anesthetic only or local anesthetic with a steroid in each 60 patient group.
RESULTS: The primary outcome measure was significant improvement, defined as pain relief and functional status improvement of at least 50% from baseline, which was reported at 24-month follow-ups in 72% who received local anesthetic only with a lumbar interlaminar approach and 54% who received local anesthetic only with a caudal approach. In patients receiving local anesthetic with a steroid, the response rate was 67% for those who had a lumbar interlaminar approach and 68% for those who had a caudal approach at 12 months. The response was significantly better in the lumbar interlaminar group who received local anesthetic only, 77% versus 56% at 12 months and 72% versus 54% at 24 months.
CONCLUSION: This assessment shows that in patients with axial or discogenic pain in the lumbar spine after excluding facet joint and SI Joint pain, epidural injections of local anesthetic by the caudal or lumbar interlaminar approach may be effective in managing chronic low back pain with a potential superiority for a lumbar interlaminar approach over a caudal approach.

Entities:  

Keywords:  Chronic low back pain; axial low back pain; caudal epidural injections; lumbar discogenic pain; lumbar interlaminar epidural injections.

Mesh:

Substances:

Year:  2015        PMID: 25678838      PMCID: PMC4323359          DOI: 10.7150/ijms.10870

Source DB:  PubMed          Journal:  Int J Med Sci        ISSN: 1449-1907            Impact factor:   3.738


Introduction

Low back pain is a major disabling condition that has a substantial social, economic, and health care impact and is increasing in prevalence 1-16. An assessment by the US Burden of Disease Collaborators reported low back pain as the number one cause of disability 1. Even though modalities for managing chronic low back pain continue to increase, the accurate cause of low back pain is determined in a very small proportion of patients, with disc herniation and spinal stenosis contributing to pain in a minority of patients, identified with ease and managed with therapies based on moderate evidence 4, 17, 18. A multitude of treatment modalities, including surgical interventions, conservative modalities, chiropractic therapy, drug therapy, and interventional therapies continue to increase at a pace considered as uncontrollable, with escalating health care costs associated with numerous complications and the failure of some therapies 4, 6-19. The accurate cause of low back pain is not determined in the majority of patients and in the cases where it is determined, costs, disability, and failed therapies are escalating.

Pathophysiology

The intervertebral disc has long been considered a common source of low back pain with pain caused by disc herniation or with pain emanating from pathologic changes within the disc itself 4, 20-23. Discogenic pain was proposed even earlier than disc herniation with reports of discogenic pain published in 1932 and disc herniation in 1934 20, 24, 25. Pain originating from intervertebral discs without disc herniation has been described as discogenic pain, internal disc disruption, and painful degenerative disc disease 20-23. However, discogenic pain has been poorly defined and its existence itself is being questioned with rather exceedingly controversial diagnostic and treatment modalities 4, 6-8, 10, 11, 14-16, 26-31. Debate and controversies in reference to discogenic pain and its management are based on a lack of consensus on the definition of discogenic pain itself, poor prognosis with expensive surgical care, a lack of extensive published data from nonsurgical care, and the escalating utilization of multiple modalities and overall health care costs 4, 6-8, 10, 11, 14-16, 26-31. While intervertebral disc degeneration is an age-related process that is asymptomatic in most individuals, pathologic degeneration can be a major source of pain and disability 4, 20-22. “Discogenic low back pain” refers specifically to the pain caused by internal disc disruption (IDD) as proposed by Crock 32 as a condition marked by alteration in the internal structure and metabolic functions of the intervertebral disc. However, discogenic pain also has been described as a separate entity 20-22. Consequently, the prevalence of pain due to IDD was reported to be 39% and 42% in patients suffering with chronic low back pain33, 34, in contrast to primary lumbar discogenic pain which was reported in 26% when no other cause was suspected 35. Peng et al 21 assessed the natural history of discogenic low back pain with IDD in 156 patients which constituted 56% of the sample and showed 87% of the patients continued their symptoms or suffered with additional symptoms. Debate not only exists concerning the diagnosis, but also with therapeutic modalities. There have been dismal results with various surgical and nonsurgical interventions and a natural history of discogenic pain which continues to be present even 4 years after the failure of conservative management modalities 20-22.

Epidural Injections

Epidural injections for managing chronic axial or discogenic pain is not well established and not well-known, but continually debated and appears to be one of the most common interventions performed for managing axial low back pain without disc herniation4, 10, 11, 14-16, 20, 36-38. The evidence continues to emerge in reference to the role of epidural injections for managing axial or discogenic low back pain. In the past, multiple studies included patients without separating disc herniation from discogenic pain as well as without eliminating facet joint pain or sacroiliac joint pain, which has led to an inordinately high failure rate. As an alternative to surgical fusion or intradiscal therapies, epidural injections have been proposed 36-38. Their effectiveness has been demonstrated in randomized controlled trials and systematic reviews 4, 10, 11, 14-16, 20, 36-38. However, care must be taken to exclude patients with facet joint or sacroiliac joint pain. Manchikanti et al 36, 37, in 2 randomized controlled trials with 120 patients in each trial, reported significant improvement as defined by the criteria of 50% or more reduction in pain scores and improvement in functional status.

Objectives

Comparative studies are not available on the various approaches for managing chronic lumbar discogenic pain after ruling out facet joint and sacroiliac joint pain. We sought to evaluate the efficacy of the caudal and lumbar interlaminar approaches of epidural injections in managing chronic, intractable, persistent axial or discogenic low back pain after ruling out facet joint and sacroiliac joint pain and after partial or no response to conservative management with a 2-year follow-up, utilizing 2 published randomized trials with identical protocols 36, 37.

Materials and Methods

This assessment was performed from 2 previously published randomized controlled trials 36, 37 conducted in a tertiary referral interventional pain management center in the United States by the same group of investigators utilizing identical protocols. The trials 36, 37 and this analysis were conducted with internal resources. Institutional Review Board approval was obtained for both trials and they were registered with the US Clinical Trial Registry with assigned numbers of National Clinical Trial (NCT) NCT00370799 and NCT00681447. The trials were conducted based on Consolidated Standards of Reporting Trials guidance. Both manuscripts 36, 37 included in this analysis have described in detail the patients, pre-enrollment assessment results, interventions, inclusion and exclusion criteria, description of interventions, additional and cointerventions, objectives and outcomes, randomization, sequence generation, allocation concealment, implementation, blinding, sample size calculation, and appropriate statistical methodology. All the patients who participated in these trials were recruited from a practice that provides interventional pain management services. Salient features are described below.

Interventions

The protocols specified caudal and lumbar interlaminar epidural injections. The patients in both trials were divided into 60 patients in each group who received either local anesthetic only or local anesthetic with a steroid. For caudal epidural injections, a total of 10 mL of solution (10 mL of 0.5% lidocaine or 9 mL of lidocaine with 1 mL of steroid) and for lumbar interlaminar epidural injections, a total of 6 mL of solution (6 mL of 0.5% lidocaine or 5 mL of lidocaine with 1 mL of steroid) were injected.

Inclusion and Exclusion Criteria

Inclusion criteria focused on chronic lumbar axial or discogenic pain without disc herniation, radiculitis, facet joint pain, or sacroiliac joint pain in patients over 18 years of age with at least 6 months of function-limiting low back pain. The facet joint pain and sacroiliac joint pain were ruled out by controlled comparative local anesthetic blocks 4, 33-35, 39-42, whereas disc herniation was excluded by radiologic investigations and clinical assessment. Exclusion criteria included previous lumbar surgery, central or foraminal spinal stenosis, radiculitis without disc herniation, facet joint pain, and sacroiliac joint pain.

Description of Interventions

All the procedures were performed in a sterile operating room under fluoroscopy by one physician with appropriate monitoring and intravenous sedation as indicated. Caudal epidural injections were performed by entering the epidural space through the sacral hiatus confirmed by contrast medium injection; whereas, lumbar interlaminar epidural injections were performed with the loss of resistance technique and confirmed under fluoroscopy with contrast medium injection.

Outcomes

Outcome measurements were carried out at various periods up to 24 months with significant improvement defined as at least 50% improvement in pain relief and functional status. The Numeric Pain Rating Scale (NRS) and Oswestry Disability Index (ODI), both of which are validated measures, were utilized in these trials 36, 37.

Sample Size

A sample size was determined for both randomized trials. A total of 110 patients, 55 patients in each group for each trial, were required. Considering a 0.05, 2-sided significance level, a power of 80%, an allocation ratio of 1:1, and accounting for a possible 10% attrition/noncompliance rate, 120 patients were included in each trial 36, 37.

Statistical Analysis

The Statistical Package for Social Sciences version 9.01 (SPSS Inc, Chicago, IL) was utilized. Chi-square (Fisher's exact test where necessary) and t test were used for categorical and continuous data comparison, respectively. Patients' outcomes were measured at 6 points in time, thus a repeated measures analysis of variance was performed with a post hoc analysis Bonferroni correction. A P value of less than 0.05 was considered significant. An intent-to-treat analysis was performed after a sensitivity analysis in the original trials 36, 37.

Results

Patient flow is shown in Fig. 1 of both manuscripts 36, 37. As described in these manuscripts, an intent-to-treat analysis was performed and all 60 patients in each trial were included in the analysis. There was an overall follow-up rate at the end of 2 years of 82% in the caudal trial and 78% in the lumbar interlaminar trial.
Figure 1

Illustration of reduction (at least 50%) in pain rating scores and Oswestry Disability Index scores from baseline (only responsive patients).

Recruitment

Patients were recruited from January 2007 through August 2008 for the caudal trial 35 and from January 2008 through May 2010 for the lumbar interlaminar trial 37.

Baseline Characteristics

Baseline demographic and clinical characteristics of each trial are shown in Table 1. There were no statistically significant differences between the caudal and lumbar interlaminar trials except for mean age and ODI scores.
Table 1

Baseline demographic and clinical characteristics.

Interlaminar (120)Caudal (120)P value
GenderMale32% (38)29% (35)0.673
Female68% (82)71% (85)
AgeMean ± SD42.0 ± 11.646.2 ± 14.30.013
WeightMean ± SD189.9 ± 55.8183.3 ± 51.90.344
HeightMean ± SD66.1 ± 3.965.5 ± 3.70.218
Body Mass IndexMean ± SD30.5 ± 8.529.9 ± 7.90.599
Duration of Pain (months)Mean ± SD116.6 ± 99.495.5 ± 86.00.080
Onset of PainGradual68% (82)65% (78)0.681
Injury32% (38)35% (42)
Numeric Pain Rating Scale ScoresMean ± SD7.8 ± 0.98.0 ± 0.90.242
Oswestry Disability Index ScoresMean ± SD29.9 ± 4.928.3 ± 4.90.014

Analysis of Outcomes

Pain Relief and Functional Assessment

Table 2 shows the comparative results of outcomes representing the results of repeated measures analysis of both trials over 24 months. There were no significant differences noted either in NRS or ODI scores with local anesthetic only compared to local anesthetic with a steroid or caudal compared to lumbar interlaminar epidurals. There were significant differences with improvement in all parameters from baseline to 24-month follow-up. However, the lumbar interlaminar group fared better when all patients were considered in reference to average total relief for one year and also for 2 years. Further, nonresponsive patients were inordinately high, with 42 in the caudal group, whereas there were only 11 in the lumbar interlaminar group.
Table 2

Comparative results of Numeric Pain Rating Scale scores and Oswestry Disability Index scores for 2 years (Mean ± SD) of lumbar interlaminar and caudal epidural injections.

Numeric Pain Rating ScaleOswestry Disability Index
InterlaminarCaudalInterlaminarCaudal
Baseline7.8 ± 0.98.0 ± 0.929.9 ± 4.928.3 ± 4.9
3 months3.5* ± 1.03.9* ± 1.614.7* ± 4.715.4* ± 6.5
6 months3.7* ± 1.13.9* ± 1.714.9* ± 5.015.3* ± 7.0
12 months3.7* ± 1.24.1* ± 1.715.0* ± 5.715.4* ± 6.9
18 months3.9* ± 1.34.2* ± 1.814.9* ± 5.515.5* ± 7.1
24 months3.7* ± 1.44.2* ± 1.814.7* ± 5.615.7* ± 7.1
Group Difference0.2400.011
Time Difference0.0010.000

A lower value indicates better condition.

* significant difference with baseline values within the group (P < 0.001).

Figures 1 and 2 show the proportion of patients with significant improvement in pain and function of at least 50%. As shown in Figure 1, in the responsive patients, when local anesthetic was administered alone, significant improvement was seen in 78% in the lumbar interlaminar group and 84% in the caudal group compared to 70% and 73% at 24 months in patients who received local anesthetic with a steroid. A comparison of the results in all patients showed improvement with local anesthetic alone in 72% in the lumbar interlaminar group and 54% in the caudal group, whereas it was 67% and 60% with local anesthetic with a steroid at 24 months. Improvement was in a significantly higher proportion of patients receiving lumbar interlaminar injections of local anesthetic only at 12 months and 24 months.
Figure 2

Illustration of reduction (at least 50%) in pain rating scores and Oswestry Disability Index scores from baseline (all patients).

Therapeutic Procedural Characteristics

Therapeutic procedural characteristics with procedural frequency, average relief per procedure, and average total relief in weeks over a period of 2 years is shown in Table 3. Among the patients who were responsive, lumbar interlaminar and caudal injections both showed over 72 weeks average relief for 2 years compared to all patients who showed approximately 66 weeks in the lumbar interlaminar group and 53 weeks in the caudal group. The average procedures for 2 years was 6 with an average relief per procedure of 11 to 12 weeks. Lumbar interlaminar epidural injections were superior with an average total relief of one year and 2 years compared to caudal injections due to a high nonresponsive rate in the caudal trial.
Table 3

Therapeutic procedural characteristics with procedural frequency, average relief per procedure, and average total relief in weeks over a period of 2 years.

Responsive PatientsNonresponsive PatientsAll Patients
Interlaminar (109)Caudal (78)Interlaminar (11)Caudal (42)Interlaminar (120)Caudal (120)
Average Number of Procedures for One Year4.0 ± 0.94.0 ± 1.01.9 ± 1.22.8 ± 1.53.8* ± 1.13.6 ± 1.3
Average Number of Procedures for Two Years6.4 ± 2.26.1 ± 2.21.9 ± 1.23.1 ± 2.06.0* ± 2.55.0 ± 2.5
Average Relief for First procedure6.3 ± 4.16.8 ± 5.40.7 ± 0.91.9 ± 2.35.8 ± 4.25.1 ± 5.1
Average Relief for Second Procedure10.6 ± 10.512.2 ± 11.60.9 ± 1.01.6 ± 1.910.1 ± 10.59.0 ± 10.9
After Initial 2 Procedures12.7 ± 3.6 (475)13.4 ± 7.2 (316)3.2* ± 3.3 (5)8.7 ± 5.8 (53)12.6 ± 3.7 (480)12.7 ± 7.2 (369)
Average Relief per Procedure11.4 ± 5.8 (693)12.1 ± 8.2 (472)1.3* ± 2.0 (21)4.6 ± 5.3 (129)11.1 ± 6.0 (714)10.5 ± 8.2 (601)
Average Total Relief for One Year (Weeks)39.3 ± 12.342.0 ± 9.92.5 ± 4.010.1 ± 12.235.9* ± 15.930.8 ± 18.6
Average Total Relief for Two Years (Weeks)72.2 ± 29.273.0 ± 28.12.5 ± 4.014.3 ± 22.765.8* ± 34.452.9 ± 38.3

* - Significant difference with caudal epidurals.

Adverse Events

No major adverse events were reported in either trial.

Discussion

This analysis shows the efficacy of caudal and lumbar interlaminar epidural injections for managing chronic persistent axial or discogenic pain without disc herniation, facet joint pain, or sacroiliac joint pain at 24 months in 54% and 60% of the patients in the caudal group who received local anesthetic only or local anesthetic with a steroid and 72% and 67% of the patients in the lumbar interlaminar group who received local anesthetic only or local anesthetic with a steroid. However, when only responsive patients were considered with improvement of at least 3 weeks with the 2 initial procedures, significant improvement was seen in 78% and 84% who received local anesthetic only in the lumbar interlaminar and caudal trials; whereas it was 70% and 73% for local anesthetic with a steroid. The proportion of patients improving when all patients were considered who received local anesthetic only was higher in the lumbar interlaminar group (54% versus 72%), whereas it was similar in patients who received local anesthetic with a steroid, as well as in responsive patients who received local anesthetic only or with a steroid. This may be explained by the fact that 11, or 9%, of the patients in the lumbar interlaminar group were shown to be nonresponsive, compared to 42, or 35%, of the patients in the caudal trial. Thus, once patients are judged to be responsive with the initial 2 injections, caudal and lumbar interlaminar epidural injections provide similar results of efficacy. These results also explain that it may be prudent to perform lumbar interlaminar epidural injections at least initially to judge responsiveness or a significant proportion of patients may be judged nonresponsive and may be denied further treatments. When medically necessary and indicated, epidural injections may be repeated after the pain starts returning and pain relief and functional status improvement start dissipating below the 50% level in 10 to 12 weeks. Approximately 6 epidural injections per year are indicated in patients who demonstrate significant improvement with the first 2 procedures. These patients are considered to be responsive patients. While lumbar disc herniation is relatively easily diagnosed and is the most common indication for surgical intervention, diagnosing discogenic pain is poorly defined and the diagnostic methods and treatments are controversial. Similar to disc herniation, the course and prognosis of discogenic pain is considered favorable, and by some, even better, than disc herniation. Anatomically and pathophysiologically, the normal intervertebral disc is avascular and aneural, except for the outer third of the annulus fibrosis, which is innervated by sensory nerve endings from a dorsal root ganglion (DRG) 20-23. Nevertheless, as the disc degeneration advances, disc inflammation promotes axonal growth of afferent fibers innervating the disc by secreting proinflammatory mediators, such as tumor necrosis factor and interleukin-6. Further, trophic growth factor for sympathetic and sensory nerve growth factor (NGF) also stimulate the differentiation, growth, maintenance, and survival of sympathetic and sensory nerve cells. NGF has been shown to exert hyperalgesic properties by sensitization of the sensory nerves, stimulation of peripheral nociceptive neurons growing into the intervertebral disc tissues triggering pain signals, and the neurons of DRG transmitting an inflammatory signal from the spinal cord to the pain centers of the brain. This response rate is similar to epidural injections for various conditions in multiple regions of the spine 43-51. Based on widely available disc herniation literature from blind lumbar interlaminar trials, the evidence first favored caudal epidural injections, and later favored lumbar transforaminal epidural injections 4, 14-16. Recent evidence shows similar efficacy for all 3 approaches for managing chronic disc herniation in the lumbar region 43, 45, 47, 49, 50. However, there are also numerous publications with contradictory evidence, reporting a lack of efficacy for epidural injections for all pathologies utilizing all type of epidural injections - caudal, interlaminar, and transforaminal 52-58. Similarly, this assessment of 2 trials 36, 37, conducted in a practical nonacademic setting with proper methodology, not only provides appropriate information, but also provides guidance in the proper application of interventions to reduce chronic discogenic pain, improve function, and potentially have a patient return to the workforce. However, results based on a lack of an appropriate protocol and procedural guidance, as well as inappropriate provision of any type of intervention, specifically inclusion of those that are not cost-effective, lead to substantial expenses, harms the health care environment, and, finally, harms patients and their access. There have not been any randomized controlled trials for lumbar transforaminal epidural injections or other trials available for caudal or lumbar interlaminar epidural injections for managing chronic discogenic pain after excluding disc herniation, facet joint pain, and sacroiliac joint pain. This assessment essentially showed an equal efficacy in the patients who responded to the initial 2 procedures; there was a much smaller nonresponsive rate with a lumbar interlaminar approach versus a caudal approach (9% versus 35%). Further, there was no significant difference whether local anesthetics only were administered or if a steroid was added. This assessment and the primary trials may be criticized for not performing provocation discographies to determine the presence of discogenic pain and/or internal disc disruption; however, based on the evidence thus far available in the literature 4, 22, 33-38, the major structures that can cause pain are intervertebral discs (without disc herniation), facet joints, and sacroiliac joints. Since the inclusion criteria consisted of only patients without disc herniation or radiculitis, and since subsequently facet joint and sacroiliac joint pain were also excluded, the inclusion criteria are considered appropriate. In addition, it has been always claimed that patients with less than 80% pain relief after diagnostic blocks may receive any further treatments due to a lack of approval of facet or sacroiliac joint interventions, but they have been shown to respond extremely well in this setting, similar to those with disc herniation, spinal stenosis, and post lumbar surgery syndrome 4, 14-16, 36-51. In addition, practical clinical trials with a pragmatic approach which can be applied clinically and/or shown to be valid are considered essential for evidence-based medicine and comparative effectiveness research 4, 14-16, 36-51, 59, 60. The present analysis of 2 randomized trials of discogenic pain may be criticized for multiple deficiencies, including 2 separate randomized trials utilized in this analysis, the lack of provocation discography prior to enrolling patients into the trials, and the lack of a placebo group in either trial. However, assessing the efficacy of caudal and lumbar interlaminar approaches in a single trial compromises patient, provider, and assessor blinding. Placebo design for interventional techniques is extremely difficult and multiple previous designs have been criticized for their inappropriate utilization in assessing epidural injections including caudal, interlaminar, and transformational approaches [4, 14-16. Unlike epidural injections performed in managing disc herniation, there are no placebo trials available for discogenic pain either performed blindly or with fluoroscopy with any of the approaches. Multiple issues related to placebo-controlled trials are based on ample evidence that inactive substances, when injected into active structures, invariably result in various types of clinical effects, as well as placebo and nocebo effects 3, 4, 36-50, 53, 58-75. In addition, local anesthetics also have shown long-term improvement or response that is similar to steroids in clinical and experimental settings 4, 14-16, 36-51, 76-78. However, 2 appropriate placebo-designed trials have been described for interventional techniques 79, 80. Thus, it is not only essential, but also mandatory, to design appropriate placebo studies in interventional pain management settings by injecting inactive solutions into inactive structures. Further, it is crucial to determine the improvement from baseline to follow-up periods rather than depending on between-group or between-trial differences and also not to consider either short-acting or even long-acting local anesthetics as placebos.

Conclusion

This assessment shows that the 2 trials which included patients who failed to respond positively to the diagnostic criteria of 80% pain relief threshold responded with significant improvement in 78% or 70% with local anesthetic only or with a steroid in the lumbar interlaminar trial; whereas, the response rate was 84% and 73% in the caudal trial.
  76 in total

Review 1.  Diagnostic criteria and treatment of discogenic pain: a systematic review of recent clinical literature.

Authors:  Khalid M Malik; Steven P Cohen; David R Walega; Honorio T Benzon
Journal:  Spine J       Date:  2013-08-28       Impact factor: 4.166

2.  Guidelines warfare over interventional techniques: is there a lack of discourse or straw man?

Authors:  Laxmaiah Manchikanti; Ramsin M Benyamin; Frank J E Falco; David L Caraway; Sukdeb Datta; Joshua A Hirsch
Journal:  Pain Physician       Date:  2012 Jan-Feb       Impact factor: 4.965

Review 3.  What are pragmatic trials?

Authors:  M Roland; D J Torgerson
Journal:  BMJ       Date:  1998-01-24

Review 4.  Lumbar discogenic pain: state-of-the-art review.

Authors:  Nikolai Bogduk; Charles Aprill; Richard Derby
Journal:  Pain Med       Date:  2013-04-08       Impact factor: 3.750

5.  A randomized, double-blind, active-controlled trial of fluoroscopic lumbar interlaminar epidural injections in chronic axial or discogenic low back pain: results of 2-year follow-up.

Authors:  Laxmaiah Manchikanti; Kimberly A Cash; Carla D McManus; Vidyasagar Pampati; Ramsin M Benyamin
Journal:  Pain Physician       Date:  2013 Sep-Oct       Impact factor: 4.965

Review 6.  Accountable interventional pain management: a collaboration among practitioners, patients, payers, and government.

Authors:  Laxmaiah Manchikanti; Standiford Helm Ii; Vijay Singh; Joshua A Hirsch
Journal:  Pain Physician       Date:  2013 Nov-Dec       Impact factor: 4.965

7.  The prevalence and clinical features of internal disc disruption in patients with chronic low back pain.

Authors:  A C Schwarzer; C N Aprill; R Derby; J Fortin; G Kine; N Bogduk
Journal:  Spine (Phila Pa 1976)       Date:  1995-09-01       Impact factor: 3.468

8.  Placebos without deception: a randomized controlled trial in irritable bowel syndrome.

Authors:  Ted J Kaptchuk; Elizabeth Friedlander; John M Kelley; M Norma Sanchez; Efi Kokkotou; Joyce P Singer; Magda Kowalczykowski; Franklin G Miller; Irving Kirsch; Anthony J Lembo
Journal:  PLoS One       Date:  2010-12-22       Impact factor: 3.240

9.  Avoiding nocebo effects to optimize treatment outcome.

Authors:  Ulrike Bingel
Journal:  JAMA       Date:  2014-08-20       Impact factor: 157.335

10.  Two-year follow-up results of fluoroscopic cervical epidural injections in chronic axial or discogenic neck pain: a randomized, double-blind, controlled trial.

Authors:  Laxmaiah Manchikanti; Kimberly A Cash; Vidyasagar Pampati; Yogesh Malla
Journal:  Int J Med Sci       Date:  2014-02-06       Impact factor: 3.738

View more
  17 in total

1.  [Periradicular infiltration therapy : Clinical indications, technique and results].

Authors:  B Oder; S Thurnher
Journal:  Radiologe       Date:  2015-10       Impact factor: 0.635

Review 2.  Treatment of Discogenic Low Back Pain: Current Treatment Strategies and Future Options-a Literature Review.

Authors:  Lei Zhao; Laxmaiah Manchikanti; Alan David Kaye; Alaa Abd-Elsayed
Journal:  Curr Pain Headache Rep       Date:  2019-11-09

Review 3.  [Facet infiltration and periradicular therapy].

Authors:  Martin G Mack; Marc Regier; Christopher Herzog
Journal:  Radiologe       Date:  2020-02       Impact factor: 0.635

Review 4.  An update on epidural steroid injections: is there still a role for particulate corticosteroids?

Authors:  Francis T Delaney; Peter J MacMahon
Journal:  Skeletal Radiol       Date:  2022-09-29       Impact factor: 2.128

5.  Selective nerve root blocks vs. caudal epidural injection for single level prolapsed lumbar intervertebral disc - A prospective randomized study.

Authors:  Sudhir Singh; Sanjiv Kumar; Gaurav Chahal; Reetu Verma
Journal:  J Clin Orthop Trauma       Date:  2016-02-22

6.  In Response to Risks and Pitfalls of Epidural Injections during Management of Lumbar Disc Herniation: Few Comments.

Authors:  Laxmaiah Manchikanti; Joshua A Hirsch
Journal:  Korean J Pain       Date:  2015-07-01

Review 7.  What is the Role of Epidural Injections in the Treatment of Lumbar Discogenic Pain: A Systematic Review of Comparative Analysis with Fusion.

Authors:  Laxmaiah Manchikanti; Peter S Staats; Devi E Nampiaparampil; Joshua A Hirsch
Journal:  Korean J Pain       Date:  2015-04-01

8.  Prospective medium-term results of multimodal pain management in patients with lumbar radiculopathy.

Authors:  A Benditz; M Madl; M Loher; J Grifka; D Boluki; O Linhardt
Journal:  Sci Rep       Date:  2016-06-16       Impact factor: 4.379

Review 9.  The Effectiveness of Transforaminal Versus Caudal Routes for Epidural Steroid Injections in Managing Lumbosacral Radicular Pain: A Systematic Review and Meta-Analysis.

Authors:  Jun Liu; Hengxing Zhou; Lu Lu; Xueying Li; Jun Jia; Zhongju Shi; Xue Yao; Qiuli Wu; Shiqing Feng
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

10.  Therapeutic lumbar facet joint nerve blocks in the treatment of chronic low back pain: cost utility analysis based on a randomized controlled trial.

Authors:  Laxmaiah Manchikanti; Vidyasagar Pampati; Alan D Kaye; Joshua A Hirsch
Journal:  Korean J Pain       Date:  2018-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.